CA2735280A1 - Pharmaceutical safety dosage forms - Google Patents

Pharmaceutical safety dosage forms Download PDF

Info

Publication number
CA2735280A1
CA2735280A1 CA2735280A CA2735280A CA2735280A1 CA 2735280 A1 CA2735280 A1 CA 2735280A1 CA 2735280 A CA2735280 A CA 2735280A CA 2735280 A CA2735280 A CA 2735280A CA 2735280 A1 CA2735280 A1 CA 2735280A1
Authority
CA
Canada
Prior art keywords
pharmaceutical
dosage form
safety dosage
antagonist
microdosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2735280A
Other languages
English (en)
French (fr)
Inventor
Richard H. Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceuticals USA Inc
Original Assignee
Mutual Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutual Pharmaceutical Co Inc filed Critical Mutual Pharmaceutical Co Inc
Publication of CA2735280A1 publication Critical patent/CA2735280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2735280A 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms Abandoned CA2735280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/339,977 US7524515B2 (en) 2003-01-10 2003-01-10 Pharmaceutical safety dosage forms
US10/339,977 2003-01-10
CA2505661A CA2505661C (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2505661A Division CA2505661C (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms

Publications (1)

Publication Number Publication Date
CA2735280A1 true CA2735280A1 (en) 2004-07-29

Family

ID=23331375

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2735280A Abandoned CA2735280A1 (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms
CA2505661A Expired - Fee Related CA2505661C (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2505661A Expired - Fee Related CA2505661C (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms

Country Status (7)

Country Link
US (2) US7524515B2 (https=)
EP (1) EP1581188A4 (https=)
JP (1) JP2006514067A (https=)
AU (1) AU2003299826A1 (https=)
CA (2) CA2735280A1 (https=)
TW (1) TWI265812B (https=)
WO (1) WO2004062642A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
KR20030048026A (ko) * 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CN1610551A (zh) * 2001-07-06 2005-04-27 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
CA2520660C (en) * 2003-03-28 2013-08-20 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1648425B1 (en) * 2003-07-30 2007-02-21 Merrion Research I Limited Process and Machine for the Automated Manufacture of Gastro-Retentive Capsules
CA2536816A1 (en) * 2003-08-12 2005-03-03 Endo Pharmaceuticals, Inc. Method for deterring abuse of opioids by combination with non-release formulation of emetic
AU2013206525B2 (en) * 2003-11-26 2015-09-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
HRP20090363T1 (hr) * 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
CN101014360A (zh) * 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US9060950B2 (en) * 2005-06-13 2015-06-23 Paul H. Rosenberg, Proximate Concepts, LLC. Emetic embedded capsule
CA2612044C (en) * 2005-06-13 2016-02-02 Paul Rosenberg Emetic embedded capsule
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
DK2101740T3 (da) * 2006-12-04 2013-11-18 Orexo Ab Nye ikke-misbrugs-farmaceutiske sammensætninger omfattende opioider
EP2079456B1 (en) 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
EP2586428B1 (en) * 2007-04-26 2023-11-08 Sublimity Therapeutics Limited Manufacture of multiple minicapsules
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2254561A2 (en) * 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
ES2414856T3 (es) * 2008-12-12 2013-07-23 Paladin Labs Inc. Formulaciones de fármaco narcótico con potencial de adicción disminuido
ES2649112T3 (es) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
HUE034955T2 (en) 2010-12-22 2018-03-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
SMT202100546T1 (it) 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
EP3294278B1 (en) * 2015-05-13 2022-05-11 4P-Pharma Apomorphine for the treatment of methylphenidate induced hyperactivity
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2022247952A1 (zh) * 2021-05-28 2022-12-01 上海博志研新药物技术有限公司 硝苯地平美托洛尔缓释组合物、其制备方法及应用
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35839A (en) * 1862-07-08 Improvement in vegetable-cutters
US6091A (en) * 1849-02-06 Improvement in rotary-cutter plows
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4371539A (en) * 1981-04-27 1983-02-01 American Home Products Corporation CNS Stimulants
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4529583A (en) 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB2162061B (en) 1984-05-03 1988-11-16 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4981468A (en) * 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5547878A (en) * 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5856493A (en) 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9710726D0 (en) 1997-05-23 1997-07-16 Nycomed Imaging As Compound
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
EP1450824A4 (en) * 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms

Also Published As

Publication number Publication date
US7919120B2 (en) 2011-04-05
JP2006514067A (ja) 2006-04-27
CA2505661C (en) 2011-06-14
EP1581188A1 (en) 2005-10-05
EP1581188A4 (en) 2006-04-05
AU2003299826A1 (en) 2004-08-10
US7524515B2 (en) 2009-04-28
WO2004062642B1 (en) 2004-10-21
WO2004062642A1 (en) 2004-07-29
TWI265812B (en) 2006-11-11
US20030124061A1 (en) 2003-07-03
TW200505506A (en) 2005-02-16
US20090175950A1 (en) 2009-07-09
CA2505661A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
CA2735280A1 (en) Pharmaceutical safety dosage forms
AU2020391466B2 (en) Capsid inhibitors for the prevention of HIV
JP5925171B2 (ja) 医薬薬剤の加工性を改良するための固体担体粒子の使用
EP1515701B1 (en) Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
AU2005245025B2 (en) Pharmaceutical tablets comprising two or more unitary segments
DK2393485T3 (en) Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir
ME01980B (me) Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat
HUP0302455A2 (hu) Amlodipint és benazeprilt tartalmazó kombinációs gyógyszerkészítmények és alkalmazásuk
JP2006514067A5 (https=)
NO341027B1 (no) Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav
WO2004064815A8 (en) Oral dosage formulation
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
TW200944251A (en) Capsule for the prevention of cardiovascular diseases
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
KR101780739B1 (ko) 활성성분-함유 필름 코팅층을 포함하는 복합제제
KR20140145201A (ko) 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
WO2007079260A1 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
WO2007145863A2 (en) Sustained release formulation of naltrexone
KR20160060764A (ko) 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
WO2005023304A3 (en) Antimalarial compositions and manufacturing process thereof
WO2003086319A3 (en) Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
EP2275110A3 (en) Cladribine regimen for treating Multiple Sclerosis
EP2720685A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
JP2009512705A5 (https=)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141218